RT-QuIC: a highly promising diagnostic method for neurodegenerative diseases-advantages and limitations

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389030%3A_____%2F25%3A00637642" target="_blank" >RIV/61389030:_____/25:00637642 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/25:10159361 RIV/61989592:15110/25:73631074 RIV/61989592:15310/25:73631074

Výsledek na webu

<a href="https://doi.org/10.3389/fneur.2025.1578252" target="_blank" >https://doi.org/10.3389/fneur.2025.1578252</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fneur.2025.1578252" target="_blank" >10.3389/fneur.2025.1578252</a>

Jazyk výsledku

angličtina

Název v původním jazyce

RT-QuIC: a highly promising diagnostic method for neurodegenerative diseases-advantages and limitations

Popis výsledku v původním jazyce

Although it has been more than 200 years since Parkinson's disease was described, we have not established biomarkers for its definitive diagnosis yet. Moreover, there is a similar case for the entire group of alpha-synucleinopathies, which are all characterized by the pathological accumulation of aggregated alpha-synuclein (alpha-Syn) in the brain and other tissues. In different biological materials (blood, cerebrospinal fluid, saliva, or skin), alpha-Syn exists in various conformations and various aggregated states depending on the surrounding environment. Lewy bodies have been considered a pathognomonic feature of Parkinson's disease for over 100 years, and alpha-Syn has been known to be a key component of Lewy bodies for over 25 years, making it possible to confirm the diagnosis by post-mortem examination of brain tissue. To overcome these limitations, novel analytical seed amplification assays (SAAs) were introduced, and they quickly became one of the most effective diagnostic tools for antemortem detection of alpha-synucleinopathies. As they require minimal sample amounts to provide consistent, rapid, and reliable results, SAAs are ideally suited for biomarker determination. This review examines SAA analytical and detection methods, their advantages and strengths, as well as their limitations and shortcomings that need to be addressed to establish a reliable and reproducible protocol. This could serve as a diagnostic methodology worldwide to determine the presence of pathological alpha-Syn protein at early stages and help develop effective disease-modifying treatment.

Název v anglickém jazyce

RT-QuIC: a highly promising diagnostic method for neurodegenerative diseases-advantages and limitations

Popis výsledku anglicky

Although it has been more than 200 years since Parkinson's disease was described, we have not established biomarkers for its definitive diagnosis yet. Moreover, there is a similar case for the entire group of alpha-synucleinopathies, which are all characterized by the pathological accumulation of aggregated alpha-synuclein (alpha-Syn) in the brain and other tissues. In different biological materials (blood, cerebrospinal fluid, saliva, or skin), alpha-Syn exists in various conformations and various aggregated states depending on the surrounding environment. Lewy bodies have been considered a pathognomonic feature of Parkinson's disease for over 100 years, and alpha-Syn has been known to be a key component of Lewy bodies for over 25 years, making it possible to confirm the diagnosis by post-mortem examination of brain tissue. To overcome these limitations, novel analytical seed amplification assays (SAAs) were introduced, and they quickly became one of the most effective diagnostic tools for antemortem detection of alpha-synucleinopathies. As they require minimal sample amounts to provide consistent, rapid, and reliable results, SAAs are ideally suited for biomarker determination. This review examines SAA analytical and detection methods, their advantages and strengths, as well as their limitations and shortcomings that need to be addressed to establish a reliable and reproducible protocol. This could serve as a diagnostic methodology worldwide to determine the presence of pathological alpha-Syn protein at early stages and help develop effective disease-modifying treatment.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Frontiers in Neurology

ISSN

1664-2295

e-ISSN

1664-2295

Svazek periodika

16

Číslo periodika v rámci svazku

MAY 27

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

11

Strana od-do

1578252

Kód UT WoS článku

001504737600001

EID výsledku v databázi Scopus

2-s2.0-105007806599